CIN-109, CIN-110, CIN-209 and CIN-210 are series of mono and combination therapies for the treatment of obesity.
CIN-109
Phase 2
CIN-110
Phase 1
CIN-209
Pre-clinical
CIN-210
Pre-clinical
CIN-109, CIN-110, CIN-209, CIN-210
OVERVIEW:
CinFina’s portfolio of obesity therapeutics include mono- and combination- therapies designed to support healthy weight loss. The portfolio was licensed from Janssen Pharmaceuticals and includes:
- CIN-109, a Phase 1, first-in-class growth differentiation factor 15 (GDF-15) analog. GDF-15 is a stress-induced “gut-brain” cytokine with multiple effects including appetite regulation leading to weight loss. Phase 1 SAD & MAD studies have been completed. Phase 2 planning and initiation is underway.
- CIN-110, a potent and highly selective, large molecule gut hormone peptide YY (PYY) analogue which activates the G protein coupled Y2 receptor of the hypothalamus. PYY analogues are thought to result in weight loss due to reduction in food intake. CIN-110 is expected to enter Phase 1 clinical trials in 2024.
- CIN-209 is a dual agonist consisting of a glucagon like peptide-1 (GLP-1) together with a GDF-15 analog. In combination of the appetite suppressant activity of GDF-15 with the metabolic effects of the GLP-1 receptor agonist, it has the potential to induce weight loss above either of the moieties can do alone.
- CIN-210 is a dual-agonist consisting of a GLP-1 together with a PYY. In combination of the appetite suppressant activity of PYY with the metabolic effects of the GLP-1 receptor agonist, it has the potential to induce weight loss above either of the moieties can do alone.
OBESITY
Metrics:
<10% of adults with obesity are currently using or
have ever used anti-obesity therapies
KFF.org Poll 2023
40% Loss in lean body mass observed with GLP-1 therapy
Wilding JP et al, NEJM, 2021
50% of patients discontinue GLP-1 therapies within 1 year. 70% quit within year 2. Tolerability continues to be the major reason.
Weiss Tet al, BMJ Open Diab Res Care 2022
66% Of the weight is regained within a year off GLP-1.
Wilding JP et al, Diab Obesity and Metab, 2022
Sources:
Bryan, Stierman, et al. NHSR 158. National Health and Nutrition Examination Survey 2017–March 2020 Pre-Pandemic Data Files. 14 June 2021, stacks.cdc.gov/view/cdc/106273.
Morgan Stanley
Fujioka, K, et al. “The Relationship between Early Weight Loss and Weight Loss at 1 Year with Naltrexone ER/Bupropion ER Combination Therapy.” International Journal of Obesity, vol. 40, no. 9, 22 June 2016, pp. 1369–1375, 10.1038/ijo.2016.67. Accessed 15 Apr. 2020.
Bryan, Stierman, et al. NHSR 158. National Health and Nutrition Examination Survey 2017–March 2020 Pre-Pandemic Data Files. 14 June 2021, stacks.cdc.gov/view/cdc/106273.
Morgan Stanley
Fujioka, K, et al. “The Relationship between Early Weight Loss and Weight Loss at 1 Year with Naltrexone ER/Bupropion ER Combination Therapy.” International Journal of Obesity, vol. 40, no. 9, 22 June 2016, pp. 1369–1375, 10.1038/ijo.2016.67. Accessed 15 Apr. 2020.
REASONS
TO BELIEVE
GDF-15
- GDF-15, when combined with a GLP-1 results in maintenance of energy expenditure, and thus, an improved quality of weight loss where lean mass is preserved (body composition)
- When used in combination, could allow for a lower dose of the GLP-1 and thereby improve tolerability
- Enhance the durability of the weight loss
PYY
- PYY as monotherapy or added to a GLP-1 may be effective for weight loss
- PYY is different and synergistic with GLP-1 therapies:
- Satiety vs Motivation/Desire
- Ability to improve side effect profile (via lower dose of GLP-1 when co-administered)
- Synergistic effect with GLP-1 (more weight loss)
- Viable option for personalized medicine in treatment of obesity (non-responders, maintenance post GLP-1 therapy)
Both programs offer dual agonist (GDF-15 / GLP-1 and PYY / GLP-1) next generation therapies, giving patients and physicians options with different mechanisms of action in a single injection
